A team of researchers have developed a novel machine-learning framework that distinguishes between low and high-risk prostate cancer with more precision than ever before.

The framework, described in a paper published in Scientific Reports, intends to help physicians and in particular, radiologists in identifying more accurate treatment options for prostate cancer patients - to decrease the chance of unnecessary clinical intervention. 

Prostate cancer is one of the leading causes of cancer death in American men, second only to lung cancer.

While recent advances in prostate cancer research have saved many lives, objective prediction tools have, until now, remained an unmet need.

At present, the standard methods used to assess prostate cancer risk are multiparametric magnetic resonance imaging (mpMRI), which detects prostate lesions, and the Prostate Imaging Reporting and Data System, version 2 (PI-RADS v2), a five-point scoring system that classifies lesions found on the mpMRI.

Together, these tools are intended to soundly predict the likelihood of clinically significant prostate cancer.

However, PI-RADS v2 scoring is subjective and does not distinguish clearly between intermediate and malignant cancer levels (scores 3, 4, and 5), often leading to differing interpretations among clinicians.

Combining machine learning with radiomics - a branch of medicine that uses algorithms to extract large amounts of quantitative characteristics from medical images has been proposed as an approach to remedy this drawback.

However, other studies have only tested a limited number of machine learning methods to address this limitation.

In contrast, the researchers developed a predictive framework that rigorously and systematically assessed many such methods to identify the best-performing one.

The framework also leverages larger training and validation data sets than previous studies did.

As a result, researchers were able to classify patients' prostate cancer with high sensitivity and an even higher predictive value.

"By rigorously and systematically combining machine learning with radiomics, our goal is to provide radiologists and clinical personnel with a sound prediction tool that can eventually translate to more effective and personalised patient care," said Gaurav Pandey, Assistant Professor of Genetics and Genomic Sciences at the Icahn School of Medicine at Mount Sinai and senior corresponding author of the publication. "The pathway to predicting prostate cancer progression with high accuracy is ever improving, and we believe our objective framework is a much-needed advancement.

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine